Effects of alkalization therapy for hepatocellular carcinoma: a retrospective study
Not Applicable
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000049949
- Lead Sponsor
- Japanese Society on Inflammation and Metabolism in Cancer
- Brief Summary
The median OS from the start of alkalization therapy inpatients with a urine pH of >= 7.0 was not reached (n = 12, 95% CI = 3.0-not reached), which was significantly longer than that in patients with a pH of < 7.0(15.4 months, n = 17, 95% CI = 5.8-not reached, p < 0.05). The addition of alkalization therapy to standard therapies may beassociated with more favorable outcomes in HCC patients with increased urinepH after alkalization therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who could not follow the alkalization therapy and/or visited our clinic less than 3 times.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival (OS) from diagnosis OS from the start of alkalization therapy Urine pH before and after alkalization therapy
- Secondary Outcome Measures
Name Time Method